Product Information
Registration Status: ActiveSIN13015P
OVIDREL SOLUTION FOR INJECTION 250mcg is approved to be sold in Singapore with effective from 2004-07-13. It is marketed by MERCK PTE LTD, with the registration number of SIN13015P.
This product contains Choriogonadotropin Alfa 250mcg in the form of INJECTION, SOLUTION. It is approved for SUBCUTANEOUS use.
This product is manufactured by Merck Serono S.p.A. in ITALY.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Product Reference
Important Note: For generic product, the SPC/PIL provided may not be brand specific.
{{/items}} {{^items}}Description
Recombinant human chorionic gonadotropin with 2 subunits, alpha = 92 residues, beta = 145 residues, each with N-and O-linked carbohydrate moieties linked to ASN-52 and ASN-78 (on alpha subunit) and ASN-13, ASN-30, SER-121, SER-127, SER-132 and SER-138 (on beta subunit). The primary structure of the alpha-chain of r-hCG is identical to that of the alpha-chain of hCG, FSH and LH.
Indication
For the treatment of female infertility
Mechanism of Action
Choriogonadotropin alfa binds to the Follicle stimulating hormone receptor which results in ovulation in the absence of sufficient endogenous Luteinizing hormone.
Pharmacokinetics
- Absorption
- The mean absolute bioavailability following a single subcutaneous injection to healthy female volunteers is about 40%.
- Distribution
- * 5.9 ± 1.0 L
- Metabolism
- Elimination
Clearance
* 0.29 +/- 0.04 L/h [healthy down-regulated females]
Active Ingredient/Synonyms
Choriogonadotropin alpha | Chorionic gonadotropin (recombinant) | Choriogonadotropin alfa |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.